206 related articles for article (PubMed ID: 10408492)
21. Warnings on venous thromboembolism risks may have been premature. New data may lead to change in use of third-generation OCs.
Contracept Technol Update; 1997 Dec; 18(12):145-8. PubMed ID: 12348219
[TBL] [Abstract][Full Text] [Related]
22. Oral contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making?
Westhoff CL
Contraception; 1996 Jul; 54(1):1-3. PubMed ID: 8804800
[TBL] [Abstract][Full Text] [Related]
23. The risk of venous thromboembolism in users of postcoital contraceptive pills.
Vasilakis C; Jick SS; Jick H
Contraception; 1999 Feb; 59(2):79-83. PubMed ID: 10361621
[TBL] [Abstract][Full Text] [Related]
24. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
25. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
[TBL] [Abstract][Full Text] [Related]
26. Oral contraceptive use before and after the latest pill scare in The Netherlands. Changes in oral contraceptive use and how users change.
de Vries CS; van den Berg PB; de Jong-van den Berg LT
Contraception; 1998 Apr; 57(4):247-9. PubMed ID: 9649916
[TBL] [Abstract][Full Text] [Related]
27. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
28. Risk of venous thromboembolism with third-generation oral contraceptives: A review.
Weiss G
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 2):295-301. PubMed ID: 9988833
[TBL] [Abstract][Full Text] [Related]
29. The 1995 pill scare revisited: anatomy of a non-epidemic.
Spitzer WO
Hum Reprod; 1997 Nov; 12(11):2347-57. PubMed ID: 9436662
[TBL] [Abstract][Full Text] [Related]
30. Another pill scare -- should we audit its impact?
Bromham DR
Audit Unit News; 1996 Jan; 1(4):2-3. PubMed ID: 12346948
[TBL] [Abstract][Full Text] [Related]
31. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
32. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women.
Heinemann LA; Lewis MA; Thorogood M; Spitzer WO; Guggenmoos-Holzmann I; Bruppacher R
BMJ; 1997 Dec; 315(7121):1502-4. PubMed ID: 9420491
[TBL] [Abstract][Full Text] [Related]
33. Bias versus causality: interpreting recent evidence of oral contraceptive studies.
Spitzer WO
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S43-50. PubMed ID: 9753310
[TBL] [Abstract][Full Text] [Related]
34. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
Heinemann LA; Dinger JC; Assmann A; Minh TD
Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
[TBL] [Abstract][Full Text] [Related]
35. The truth about oral contraceptives and venous thromboembolism.
Shulman LP; Goldzieher JW
J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
[TBL] [Abstract][Full Text] [Related]
36. Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.
Beaumont V; Lemort N; Beaumont JL
Eur Heart J; 1991 Nov; 12(11):1219-24. PubMed ID: 1782953
[TBL] [Abstract][Full Text] [Related]
37. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
38. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
39. Oral contraceptive pills and the risk of venous thromboembolism.
Prog Hum Reprod Res; 1996; (39):2-3. PubMed ID: 12292198
[TBL] [Abstract][Full Text] [Related]
40. Selective prescribing of third generation oral contraceptives (OCs).
Jamin C; de Mouzon J
Contraception; 1996 Jul; 54(1):55-6. PubMed ID: 8804809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
